GCK silencing and iberdomide combination enhances anti-MM effects on MM xenograft model. Tet-on-sh-GCK-MM1.S cells were subcutaneously injected into severe combined immunodeficient beige mice. (A) Body weights were monitored every 3 days. No significant differences were observed between the different groups. (B) Subcutaneous tumor growth was measured using calipers and calculated with the volume formula: 0.5 × long diameter × (short diameter)2 for up to 75 days. Each bar represents the mean ± standard error of the mean (n = 5). ∗∗P < .01. (C) Kaplan-Meier survival analysis for the MM tumor model during 6 weeks of follow-up (n = 5 per group). Using a Log-Rank test, a survival benefit was observed for DOX vs vehicle (∗P < .05) and iberdomide + DOX vs vehicle (∗P < .05).
